Sucampo Receives $15M Milestone Payment from Abbott for AMITIZA - Abbott Laboratories (NYSE:ABT)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Sucampo Pharmaceuticals. (NASDAQ: SCMP) today announced that its subsidiary, Sucampo AG, has received a $15 million milestone payment from Abbott's (NYSE: ABT) subsidiary, Abbott Japan Co., Ltd. (Abbott), pursuant to the existing license, commercialization, and supply agreement between Sucampo Pharma Ltd. (SPL), SPI's subsidiary, and Abbott. The milestone payment was triggered by the first sale of AMITIZA® (lubiprostone) capsule 24 μg in Japan. AMITIZA is available through Abbott in Japan as a prescription medication for chronic constipation not caused by organic diseases, and was launched to primary care and specialist physicians on November 21, 2012. “For years, millions of patients in Japan have been suffering from chronic constipation,” said Sucampo's Chairman,

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release